An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy and safety profile of co-administration of BMS-790052 and BMS-650032 for 24 weeks treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Asunaprevir

Criteria

Inclusion Criteria:

• Subjects chronically infected with HCV Genotype 1

• HCV RNA viral load of ≥ 10*5* IU/mL (100,000 IU/mL) at screening

Exclusion Criteria:

• Subjects with evidence of liver cirrhosis

• Evidence of HCC

• Co-infection with hepatitis B virus, HIV